<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01392131</url>
  </required_header>
  <id_info>
    <org_study_id>OP1</org_study_id>
    <nct_id>NCT01392131</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oncoxin in Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Study to Evaluate Safety and Therapeutic Efficacy of a Nutritional Supplement 'Oncoxin' in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Organization, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Research Organization, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oncoxin is safe and results in improved survival in patients with hepatocellular carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess therapeutic efficacy and safety of Oncoxin in hepatocellular carcinoma

      To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma
      patients after administration of Oncoxin

      To see if there is reduction tumor size and or number in hepatocellular carcinoma patients
      after administration of Oncoxin

      To see if there is improvement of quality of life in hepatocellular carcinoma patients after
      administration of Oncoxin

      To see if there is improved survival in hepatocellular carcinoma patients after
      administration of oncoxin
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who have prolonged survival after receiving Oncoxin</measure>
    <time_frame>48 weeks</time_frame>
    <description>To study the number of participants who have prolonged survival after receiving Oncoxin for 24 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in serum alpha-fetoprotein level and decrease in tumor size</measure>
    <time_frame>48 weeks</time_frame>
    <description>To see whether Oncoxin results in reduction in serum alpha-fetoprotein level and decrease in tumor size in hepatocellular carcinoma patients off treatment for 24 weeks, after receiving Oncoxin for 24 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Oncoxin will be administered orally</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supportive treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients with hepatocellular carcinoma will receive supportive treatment only</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oncoxin</intervention_name>
    <description>20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks</description>
    <arm_group_label>Oncoxin will be administered orally</arm_group_label>
    <other_name>Viusid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supportive treatment</intervention_name>
    <description>patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed</description>
    <arm_group_label>Supportive treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with HCC irrespective of etiology, age, gender and status of underlying liver
             disease.

          -  Patients with HCC who are not suitable candidates for established modalities of
             treatment i.e. surgery and/or chemotherapy.

          -  Patients with HCC who have evidence of tumor metastasis

          -  Patients with HCC who are voluntarily unwilling to take established modalities of
             treatment i.e. surgery and/or chemotherapy.

          -  Patients with HCC in whom all possible treatment options have been exhausted.

        Exclusion Criteria:

          -  Patients with HCC who are suitable candidates for established modalities of treatment
             i.e. surgery and/or chemotherapy.

          -  Patients with HCC who have no evidence of tumor metastasis

          -  Patients with HCC who are willing to take established modalities of treatment i.e.
             surgery and/or chemotherapy.

          -  Patients with HCC who are voluntarily unwilling to be included in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mamun A Mahtab, MSc MD FACG</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Farabi General Hospital</name>
      <address>
        <city>Dhaka</city>
        <zip>1205</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncoxin</keyword>
  <keyword>Safety of Oncoxin</keyword>
  <keyword>Therapeutic efficacy of Oncoxin</keyword>
  <keyword>Improvement of quality of life with Oncoxin</keyword>
  <keyword>Survival benefit with Oncoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

